152 related articles for article (PubMed ID: 27035677)
1. Hormone signaling pathways as treatment targets in renal cell cancer (Review).
Czarnecka AM; Niedzwiedzka M; Porta C; Szczylik C
Int J Oncol; 2016 Jun; 48(6):2221-35. PubMed ID: 27035677
[TBL] [Abstract][Full Text] [Related]
2. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Song W; He D; Chen Y; Yeh CR; Hsu I; Huang Q; Zhang X; Chang LS; Zuo L; Chen J; Doersch KM; Chang C; Li L; Yeh S
Mol Oncol; 2018 Dec; 12(12):2055-2071. PubMed ID: 30171816
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
5. Triiodothyronine regulates cell growth and survival in renal cell cancer.
Czarnecka AM; Matak D; Szymanski L; Czarnecka KH; Lewicki S; Zdanowski R; Brzezianska-Lasota E; Szczylik C
Int J Oncol; 2016 Oct; 49(4):1666-78. PubMed ID: 27632932
[TBL] [Abstract][Full Text] [Related]
6. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
7. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
[TBL] [Abstract][Full Text] [Related]
8. [Renal cell carcinoma].
Tomita Y
Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Bergh A; Ljungberg B
Eur Urol; 2006 Dec; 50(6):1272-7. PubMed ID: 16814458
[TBL] [Abstract][Full Text] [Related]
10. Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy.
Rajandram R; Bennett NC; Wang Z; Perry-Keene J; Vesey DA; Johnson DW; Gobe GC
Pathology; 2012 Aug; 44(5):453-9. PubMed ID: 22810054
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
12. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
[TBL] [Abstract][Full Text] [Related]
15. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway.
He D; Li L; Zhu G; Liang L; Guan Z; Chang L; Chen Y; Yeh S; Chang C
Cancer Res; 2014 Aug; 74(16):4420-30. PubMed ID: 24924778
[TBL] [Abstract][Full Text] [Related]
16. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
Pan J; Mestas J; Burdick MD; Phillips RJ; Thomas GV; Reckamp K; Belperio JA; Strieter RM
Mol Cancer; 2006 Nov; 5():56. PubMed ID: 17083723
[TBL] [Abstract][Full Text] [Related]
17. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
19. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
20. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
